American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction: “Given the limited evidence, CYP2D6 testing is currently not recommended in the preventive setting” [7]. The gene discussed is CYP2D6; the disease is breast carcinoma.